ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

INZY Inozyme Pharma Inc

4.74
-0.11 (-2.27%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inozyme Pharma Inc NASDAQ:INZY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.11 -2.27% 4.74 4.39 6.00 4.80 4.64 4.76 218,848 05:00:11

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

08/05/2024 1:30pm

GlobeNewswire Inc.


Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Inozyme Pharma Charts.

Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.

A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.

Contacts

Investors:Inozyme PharmaStefan Riley, Senior Director of IR and Corporate Communications(857) 330-8871stefan.riley@inozyme.com

Media: SmithSolve Matt Pera(973) 886-9150matt.pera@smithsolve.com

1 Year Inozyme Pharma Chart

1 Year Inozyme Pharma Chart

1 Month Inozyme Pharma Chart

1 Month Inozyme Pharma Chart